Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail-Reference-Cited by-同舟云学术

Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail

Published:2019-06 Issue:2 Volume:32 Page:127-133
ISSN:1521-6926
Container-title:Best Practice & Research Clinical Haematology
language:en
Short-container-title:Best Practice & Research Clinical Haematology

Author:

Maakaron Joseph E.,Mims Alice S.

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Oncology

Reference20 articles.

1. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B;Rai;Blood,1981

2. Anthracycline dose intensification in acute myeloid leukemia;Fernandez;N Engl J Med,2009

3. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study;Preisler;Blood,1987

4. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study;Vogler;J Clin Oncol,1992

5. How can one optimize induction therapy in AML?;Luger;Best Pract Res Clin Haematol,2017

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Repurposing of Selected Antibiotics: An Emerging Approach in Cancer Drug Discovery;ACS Omega;2024-06-13

2. Recent Advances towards the Understanding of Secondary Acute Myeloid Leukemia Progression;Life;2024-02-27

3. More Than Pigments: The Potential of Astaxanthin and Bacterioruberin-Based Nanomedicines;Pharmaceutics;2023-06-26

4. HDACIs and TKIs combinations and their liposomal delivery for cancer treatment;Journal of Controlled Release;2023-06

5. NPM 1 Mutations in AML—The Landscape in 2023;Cancers;2023-02-12